We are still optimistic about the prospect of Neogenomics, and think there are still a plenty of room for price appreciation in the next 12 months.
Our call is based on the company's strong financials, business development and management credibility.
Second Quarter Revenue In Line With Our Expectation
On July 31, Neogenomics reported financial results for the second quarter ending June 30, 2013.
Revenue for the second quarter was $15.6 million, unchanged from second quarter 2012 revenue. 2Q13 revenue is also in line...
Only subscribers can access this article, which is part of the PRO research library covering 3,602 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: